Frazier Healthcare Partners acquires Altruix
Frazier Healthcare Partners has finalized the acquisition of Altruix, a behavioral health pharmacy provider focused on patients with severe mental illnesses, substance use disorders, and intellectual and developmental disabilities. The transaction grants Frazier a significant entry into the behavioral health pharmacy sector, which it has been evaluating for several years. Terms of the deal remain undisclosed.
Altruix, based in Hunt Valley, Maryland, operates 17 pharmacies throughout the Mid-Atlantic region, offering services to over 800 behavioral health providers and 32,000 patients each month. The company’s care model is designed to improve patient outcomes through clinical support, medication adherence programs, specialized packaging, and access to complex therapies tailored for serious behavioral health conditions. As part of the acquisition, Randy Hyun, a seasoned executive in pharmacy services, has been appointed as CEO. Hyun brings a robust background from his roles at Evernorth Health System Services, CarepathRx, and Aetna Medicaid, amongst others. Meanwhile, Altruix’s former CEO, Greg Ganse, will continue with the company as an investor and advisor.
The strategic rationale behind the acquisition hinges on Altruix's established position as a leader in behavioral health pharmacy. By joining forces, Frazier and Altruix aim to leverage Frazier’s healthcare expertise to scale Altruix’s operations, bolster its clinical capabilities, and enhance patient access and outcomes nationwide. General Partner at Frazier, Philip Zaorski, emphasizes Altruix's standing as a leading platform, stating that the partnership will build on its existing leadership in a complex pharmacy sector.
The acquisition takes place amidst a broader healthcare sector focusing increasingly on behavioral health, with many firms looking to expand capabilities in this growing and essential segment. Frazier’s involvement further underlines private equity's ongoing interest in healthcare investments, particularly those that present opportunities for operational enhancement and innovation in service delivery.
As Altruix transitions under new leadership, its board of directors has been strengthened with industry veterans such as Doug Present and John Rex, whose experiences are anticipated to guide strategic initiatives. The integration process, regulatory adherence, and operational ramp-up will mark key milestones in the coming months, defining Altruix's path under Frazier’s stewardship.
Deal timeline
This transaction is classified in Behavioral Health Pharmacy. Figures and status may change as sources update.